Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial

Item

http://www.wikidata.org/entity/Q57734155

Q57734155

about

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial

Item

http://www.wikidata.org/entity/Q57734155

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2018

@uk

name

Intravenous immunoglobulin wit ...... sed, open-label, phase 3 trial

@en

Intravenous immunoglobulin wit ...... sed, open-label, phase 3 trial

@nl

type

Item

label

Intravenous immunoglobulin wit ...... sed, open-label, phase 3 trial

@en

Intravenous immunoglobulin wit ...... sed, open-label, phase 3 trial

@nl

prefLabel

Intravenous immunoglobulin wit ...... sed, open-label, phase 3 trial

@en

Intravenous immunoglobulin wit ...... sed, open-label, phase 3 trial

@nl

P1476

Intravenous immunoglobulin wit ...... sed, open-label, phase 3 trial

@en

P2093

Arlene Naranjo

http://www.w3.org/2001/XMLSchema#string

Jessica A Panzer

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Julie R Park

http://www.w3.org/2001/XMLSchema#string

Katherine K Matthay

http://www.w3.org/2001/XMLSchema#string

Michael D Hogarty

http://www.w3.org/2001/XMLSchema#string

Pedro A de Alarcon

http://www.w3.org/2001/XMLSchema#string

Sheena C Tenney

http://www.w3.org/2001/XMLSchema#string

Wendy B London

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma

Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee

Autoantigen diversity in the opsoclonus-myoclonus syndrome.

High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors.

B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes.

Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.

Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004.

BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy

P304

25-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S2352-4642(17)30130-X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Susan L. Cohn

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29376112

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

P932

5783315

http://www.w3.org/2001/XMLSchema#string